

WHO mRNA Technology Transfer Programme — Afrigen's Cape Town Hub-and-Spoke Vaccine Network

City Innovation Library · Good practice · South Africa

Quality score: 81/100

Evidence strength: Descriptive / self-reported

Summary

Since 2021, WHO and the Medicines Patent Pool have backed Afrigen Biologics in Cape Town to reverse-engineer and transfer mRNA vaccine know-how to 15 partner organisations, though as of 2025 its own COVID candidate remained in pre-clinical scale-up.

Key dimensions

Dimension	Score
Evidence of impact / measured results	2/3
Transferability / demonstrated replication	3/3
Scalability	2/3
Sustainability / continuity	1/3
Innovation	3/3
Inclusiveness / equity	3/3
Multi-stakeholder collaboration	3/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-08-26

[Afrigen Biologics and Vaccines / WHO / Medicines Patent Pool](#) — accessed 2026-08-26

[WHO — mRNA Technology Transfer Programme moves to next phase \(2023\)](#) — accessed 2026-08-26

[PLOS Global Public Health — 'Our project, your problem?' case study \(2024\)](#) — accessed 2026-08-26

[Health-e News — mRNA Technology Transfer Programme Reaches Key Milestone \(2025\)](#) — accessed 2026-08-26

Cite this — Evidoria. *WHO mRNA Technology Transfer Programme — Afrigen's Cape Town Hub-and-Spoke Vaccine Network*. Persistent ID: 7215f6df-835b-42ca-91fb-f73c6bfb6312.